Latest Regenerative iPSC News

Subscribe

Pluristyx and Solesis Release New 3D Stem Cell Transfection Kit to Improve Efficiency and Reduce Toxicity

A new kit aims to streamline 3D iPSC transfection, offering higher efficiency and lower cytotoxicity for researchers and developers.

Lineage Cell Therapeutics Receives Gene-Edited Stem Cell Line for Immune System Compatibility Studies

Lineage will evaluate the new gene-edited iPSC line for immune compatibility and manufacturing potential before pursuing exclusive rights with Factor Bioscience.

Cellares Teams Up with Stanford to Automate Gene-Edited Stem Cell Therapy Manufacturing

The partnership aims to streamline production and quality testing of gene-edited hematopoietic stem cell therapies for HIV and rare diseases.

REPROCELL Launches StemEdit: AI-Designed Gene Editing System and iPSC Product Lines for Clinical Use

The new open source gene editing services are ready to help iPSC developers create off-the-shelf allogeneic cell therapies at scale.

Cellino and Polyphron Teaming Up to Scale Personalized Tissue Manufacturing Derived from iPSCs

Polyphron will use Cellino's induced pluripotent stem cells in its "autonomous tissue foundry" to reproducibly manufacture cell and tissue therapies at scale.

Chinese Study Reports Intranasal Muse Stem Cells Show Potential for Parkinson’s Treatment

Researchers report that intranasal Muse cells improved motor function and reduced neurodegeneration in a Parkinson’s mouse model.

Cellistic Unveils New Induced Pluripotent Stem Cell Manufacturing Platforms for Cancer and Regenerative Therapies

The new platforms aim to streamline large-scale production of iPSC-derived cell therapies for new indications.

BlueRock Cell Therapeutics Receives FDA Orphan Drug for its Ocular Stem Cell Therapy, OpCT-001

OpCT-001 is an iPSC-derived cell therapy for retinitis pigmentosa, and it's now entering clinical testing following Orphan Drug status.

Trailhead Biosystems Secures Additional $20 Million to Develop Induced Pluripotent Stem Cells (iPSCs)

The new funding will support Trailhead’s efforts to commercialize iPSC-derived human cells for research and drug discovery applications.

Chinese Phase 1 Parkinson’s Stem Cell Trial Reportedly Showing Promise

South China Morning Post says it spoke with the iPSC research team, who relayed that the brain stem cell implant is showing promise in Parkinson's.
Load More
x
Subscribe
Subscribe

Stay updated on Regenerative Medicine

Subscribe